Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.
Clin Case Rep
; 9(1): 148-152, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-919869
ABSTRACT
The authors urge clinicians to observe for early signs of CMV reactivation in patients presenting with gastrointestinal bleeding and intestinal perforation after receiving tocilizumab or other immunosuppressive therapy as a treatment for COVID 19. Early recognition of CMV infection and treatment will prevent life-threatening bleeding and mortality.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Case report
Language:
English
Journal:
Clin Case Rep
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS